Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
SYSTEMIC UPTAKE OF 5-AMINOSALICYLIC ACID FROM OLSALAZINE AND EUDRAGIT-L COATED MESALAZINE IN PATIENTS WITH ULCERATIVE-COLITIS IN REMISSION
Autore:
EWE K; BECKER K; UEBERSCHAER B;
Indirizzi:
SUDRING 349 D-55128 MAINZ GERMANY UNIV MAINZ,MED KLIN & POLIKLIN MAINZ GERMANY
Titolo Testata:
Zeitschrift fur Gastroenterologie
fascicolo: 4, volume: 34, anno: 1996,
pagine: 225 - 229
SICI:
0044-2771(1996)34:4<225:SUO5AF>2.0.ZU;2-D
Fonte:
ISI
Lingua:
ENG
Soggetto:
INFLAMMATORY BOWEL-DISEASE; MAINTENANCE TREATMENT; HEALTHY-VOLUNTEERS; SULFASALAZINE; METAANALYSIS; DISPOSITION; TABLETS; FOOD;
Keywords:
5-AMINOSALICYLIC ACID; 5-ASA, ACETYLATED 5-AMINOSALICYLIC ACID; SYSTEMIC UPTAKE; ULCERATIVE COLITIS; MAINTENANCE DOSE; OLSALAZINE; MESALAZINE;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
20
Recensione:
Indirizzi per estratti:
Citazione:
K. Ewe et al., "SYSTEMIC UPTAKE OF 5-AMINOSALICYLIC ACID FROM OLSALAZINE AND EUDRAGIT-L COATED MESALAZINE IN PATIENTS WITH ULCERATIVE-COLITIS IN REMISSION", Zeitschrift fur Gastroenterologie, 34(4), 1996, pp. 225-229

Abstract

Aminosalicylates are used to maintain remission in patients with ulcerative colitis. Since there are potential systemic side effects of 5-aminosalicylic acid (5-ASA) and long term treatment is necessary for maintenance therapy preparations with low rates of absorption in the small intestine would be optimal for this indication. In this trial olsalazine (Dipentum(R)), a 5-ASA dimer, and an eudragit L coated mesalazine preparation (Salofalk(R)) were compared. Patients and methods: Fifteen patients with ulcerative colitis in clinical and endoscopical remission were randomized in a cross over design. They either received 2 x 2 capsules of olsalazine 250 mg or 3 x 2 tablets mesalazine 250 mg, these being the doses recommended for maintenance therapy. After a five days equilibration period morning pre-dose serum samples and 24 hour urine were collected on two consecutive days and analyzed for 5-ASA andacetylated 5-ASA. Subsequently, patients were crossed over to receivethe alternative preparation and were evaluated after five days correspondingly. Results: Uptake of 5-ASA from mesalazine was significantly higher than from olsalazine (p < 0.0001). Plasma concentrations of 5-ASA were 3.4 times and of acetyl-5-ASA 3.2 times higher after mesalazine administration than after olsalazine. The same applies to the 24 hour 5-ASA and acetyl-5-ASA urinary excretion (median: 3.2 versus 1.0 mmol/24 hr) as well as to the percentage of administered dose (32.4 versus 17.7%). All patients finished the trial and no major systemic side effects occured with either preparation. Conclusion: Systemic uptake of5-ASA from olsalazine was significantly lower than from eudragit L coated mesalazine. Therefore, olsalazine is less likely to produce side effects and seems to be especially suited for maintenance therapy in ulcerative colitis.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 29/09/20 alle ore 20:46:15